ACET Stock — Adicet Bio Inc.: Cash, EV, Pipeline

Share price

$9.18

Market cap

$85.9M

Cash

$118.2M

Enterprise value

-$32.3M

Balance sheet

Cash	$118.2M
Debt	$0.0M
Net cash	$118.2M
Enterprise value	-$32.3M
Basic shares	9.4M shares
Fully diluted shares	12.3M shares
Fully diluted market cap	$112.5M
Cash per share	$12.57

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ACET daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	ADI-270	Phase 1/2	Clear Cell Renal Cell Carcinoma	—
Jan 12 - Feb 23	ADI-001	Phase 1	Lupus Nephritis; Autoimmune Diseases; Systemic Sclerosis (SSc)	—
May 11 - Jun 22	ADI-001	Phase 1	Rheumatoid Arthritis (RA)	—
Nov 12 - Dec 24	ADI-212	Phase 1/2	Prostate Cancer Metastatic	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Prula-cel

Phase 1 · Active Modality: allogeneic gamma delta CAR T cell therapy

Aliases prulacabtagene leucel, ADI-001

Target CD20

Indications

Lupus nephritis (LN) (Phase 1)
Systemic lupus erythematosus (SLE) (Phase 1)
Systemic sclerosis (SSc) (Phase 1)
ANCA-associated vasculitis (AAV) (Phase 1)
Idiopathic inflammatory myopathy (IIM) (Phase 1)
Stiff person syndrome (SPS) (Phase 1)
Rheumatoid arthritis (RA) (Phase 1)

Catalysts

— first half of 2026
— second half of 2026
— second half of 2026
— second half of 2026

Status note Lead product candidate. FDA Fast Track Designation: LN (Jun 2024), refractory SLE with extrarenal involvement and SSc (Feb 2025).

ADI-212

Preclinical · Active Modality: gene-edited and armored allogeneic gamma delta CAR T cell therapy (membrane-tethered IL-12 armoring, CRISPR/Cas9 MED12 disruption)

Target PSMA (prostate-specific membrane antigen)

Indications

Metastatic castration-resistant prostate cancer (mCRPC) (Preclinical)

Catalysts

— third quarter of 2026
— fourth quarter of 2026

Status note Next-generation candidate; company aims to submit a new IND or equivalent every 12-18 months.

ADI-270

Phase 1 · Terminated Modality: allogeneic gamma delta CAR T cell therapy

Indications

Metastatic/advanced clear cell renal cell carcinoma (ccRCC) (Phase 1)

Status note Development discontinued July 2025 per strategic pipeline prioritization; enrollment in Phase 1 ccRCC trial closed.

ADI-002

Stage not disclosed · Active Modality: allogeneic gamma delta CAR T cell therapy

Target Glypican-3

Partnerships Regeneron: $20M option exercise fee (Jan 2022); high single-digit royalties on net sales

Status note Regeneron-licensed program; Regeneron solely responsible at its sole cost for all development, manufacturing and commercialization.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ADI-270
Lead indication	Clear Cell Renal Cell Carcinoma
Lead phase	Phase 1/2
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06480565	Phase 1/2	Active, not recruiting	Sponsor	Adicet Therapeutics	—	Clear Cell Renal Cell Carcinoma	—
NCT07793435	Phase 1/2	Not yet recruiting	Sponsor	Adicet Therapeutics	—	Prostate Cancer Metastatic	—
NCT06375993	Phase 1	Enrolling by invitation	Sponsor	Adicet Therapeutics	—	Lupus Nephritis; Autoimmune Diseases; Systemic Sclerosis (SSc)	—
NCT07100873	Phase 1	Recruiting	Sponsor	Adicet Therapeutics	—	Rheumatoid Arthritis (RA)	—
NCT04911478	Not disclosed	Active, not recruiting	Sponsor	Adicet Therapeutics	—	Lymphoma, Follicular; Lymphoma, Mantle-Cell; Marginal Zone Lymphoma	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Adicet Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	844,787	-183,157	0.14%	2026-08-14
ADAR1 Capital Management	0	-53,827	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ACET — Adicet Bio Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders